scholarly journals Review of Insulin Listing in the National Drug Formulary of Malaysia

2016 ◽  
Vol 19 (7) ◽  
pp. A682
Author(s):  
YV Yong ◽  
WS Kua ◽  
R Lajis ◽  
FA Md Yusof
Keyword(s):  
2007 ◽  
Vol 25 (11) ◽  
pp. 979-990 ◽  
Author(s):  
Márcio Machado ◽  
Michael Iskedjian ◽  
Inés A Ruiz ◽  
Thomas R Einarson

2019 ◽  
Vol 4 (3) ◽  
pp. 28-30
Author(s):  
Yousef Ahmed Alomi ◽  
Saeed Jamaan Alghamdi ◽  
Radi Abdullah Alattyh

Author(s):  
Tran Quang Trung ◽  
Nguyen Thi Dao ◽  
Nguyen Thanh Hai ◽  
Trinh Van Lau

This study aims to investigate the influence of the formulation factors on the drug release kinetics, thereby selecting the compositions of extended-release nifedipine tablet based on the similarity coefficient f2 obtained when compared with Adalat LA tablet. The formulation factors such as: molecular weight of the polyethylene oxide (PEO) and osmotic agent amount in drug layer and push layer, semi permeable membrane thickness (estimated by coating weight gain), orifice size, type of plasticizers and ratios of coating polymer to plasticizer in semipermeable membrane were evaluated. It was found that developed tablets were able to deliver nifedipine in an approximate zero-order manner up to 20 hours and drug release profile of developed tablets was similar to that from Adalat LA tablets. The developed tablet contained: PEO N10, PEO 303 in drug layer and push layer, respectively; percentages of osmotic agent in drug layer and push layer were 10% and 30%, respectively; weight gain of semipermeable coating was 12%; and orifice size was 0.8 mm. Keywords  Nifedipine, GPKD, push-pull osmotic pump, PEO, Tlag. References [1] Vietnamese National Drug Formulary Council, Nifedipine, Vietnamese National Drug Formulary, 2nd edition, Medical Publising House, Hanoi, 2018, pp. 1056-1058 (in Vietnamese).[2] A. Nokhodchi, M.N. Momin, J. Shokri, et al., Factors affecting the release of nifedipine from a swellable elementary osmotic pump, Drug Delivery, 15 (1) (2008) 43-48. https://doi.org/10.1080/10717540701829028[3] R.K. Verma, D.M. Krishna, S. Garg, Formulation aspects in the development of osmotically controlled oral drug delivery systems, Journal of controlled release 79 (1-3) (2002) 7-27. https://doi.org/10.1016/s0168-3659(01)00550-8.[4] The United States Pharmacopeial Convention, Nifedipine Extended-Release Tablets, The United States Pharmacopeia, 41st edition, United Book Press, Baltimore, 2018, pp. 2938 - 2944.[5] V. Malaterre, J. Ogorka, N. Loggia, et al., Approach to design push–pull osmotic pumps, International Journal of Pharmaceutics 376 (1–2) (2009) 56-62. http://dx.doi.org/10.1016/j.ijpharm.2009.04.015.[6] S. Missaghi, P. Patel P, Farrell T. P., et al., Investigation of critical core formulation and process parameters for osmotic pump oral drug delivery, AAPS PharmSciTech 15 (1) (2014) 149-160. http://doi.org/10.1208/s12249-013-0040-4.[7] V. Malaterre, H. Metz, J. Ogorka , et al., Benchtop-magnetic resonance imaging (BT-MRI) characterization of push-pull osmotic controlled release systems, J Control Release 133 (1) (2009) 31-36. http://doi.org/10.1016/j.jconrel.2008.09.007.[8] Z. Zhang, W. Li, S. Nie, et al., Overcome side identification in PPOP by making orifices on both layers, International journal of pharmaceutics 371 (1-2) (2009) 1-7. http://dx.doi.org/10.1016/j.ijpharm.2008.12.006[9] C. Wu, Z. Zhao, Y. Zhao, et al., Preparation of a push–pull osmotic pump of felodipine solubilized by mesoporous silica nanoparticles with a core–shell structure, International Journal of Pharmaceutics,475 (1-2) (2014) 298 - 305 . http://dx.doi.org/10.1016/j.ijpharm.2014.08.033.[10] V. Patel, A. Chudasama, M. Nivsarkar, et al., Push-pull osmotic pump for zero order delivery of lithium carbonate: Development and in vitro characterization, Pharmaceutical development and technology, 17 (3) (2012) 375-382. http://doi.org/10.3109/10837450.2010.542577.[11] C.N. Patra, S. Swain, J. Sruti, et al., Osmotic drug delivery systems: Basics and design approaches, Recent Patents on Drug Delivery & Formulation 7(2) (2013) 1 - 12. http://doi.org/10.2174/1872211311307020007.    


Author(s):  
Azuana Ramli ◽  
Syed Mohamed Aljunid ◽  
Saperi Sulong ◽  
Faridah Aryani Md Yusof

2010 ◽  
Vol 11 (5) ◽  
pp. 633-636 ◽  
Author(s):  
Mary W Roederer ◽  
Howard L McLeod

2020 ◽  
Vol 2 (37) ◽  
pp. 43-59
Author(s):  
Gulzira Zhussupova ◽  
◽  
Didar Baidullayeva ◽  

Abstract Kazakhstan national drug formulary form is defined as - a list of medicines with proven clinical safety and efficacy, as well as orphan (rare) drugs, which is a mandatory basis for the development of medicinal formularies of medical organizations and formation of lists of procurement of medicines within the guaranteed volume of free medical care and in the system of compulsory social health insurance in the Code “On public health and health care system”. Health research data show that in 18% of cases, non-KNF drugs were prescribed in Nur-Sultan medical organizations, 86% of healthcare organizations did not analyze rational use of financial costs for medicines and analyzes of drug consumption, 90% of medicines are assigned by trade name. At the same time, polypharmacy, excessive prescription of antibiotics and injection drugs are noted. The lack of a systematic understanding of the role of CNF in the rational use of drugs reduces the effectiveness of the measures taken. The value of the Kazakhstan National Drug Formulary for the health care of the Republic of Kazakhstan is enormous, for example, for clinicians it is a public resource for doctors and serves as a reference book on medicines and pharmacotherapy based on evidence-based medicine, as well as a guide to integrate Kazakhstan's usual clinical practice into international best practice, in addition to educational a guide providing continuing education in clinical pharmacology and a restrictive list of drugs recommended for routine use in routine clinical practice. For the population, it plays the role of a guideline in the provision of medicines within the guaranteed volume of medical care and in the system of compulsory social health insurance, as well as guidance on involving civil society in the process of monitoring the rational use of medicines. This policy brief shows three policy options and visions for implementing policy options. At the same time, the existing legislative framework of Kazakhstan has all the necessary conditions to support the implementation of the proposed policy options, however, the main barriers to the implementation of policy options may be a lack of human resources, unethical promotion of medicines on the market, lack of support from the authorized body in the field of health, and there is also a lack of understanding by medical workers and the public of the role of the Kazakhstan national formulary in the rational use of medicines.


Sign in / Sign up

Export Citation Format

Share Document